Cargando...
Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
Regulatory agencies request an assessment of cardiovascular safety for all “new” oral anti-diabetic drugs in order to avoid possible negative effects on cardiovascular events. Dipeptidyl peptidase 4 inhibitors have emerged as a new therapeutic alternative for the treatment of type 2 diabetes mellitu...
Guardado en:
| Publicado en: | Cardiovasc Diabetol |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4818902/ https://ncbi.nlm.nih.gov/pubmed/27039303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-016-0379-4 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|